Clinical trial
A Randomized Phase 2 Study of Pacritinib vs. Hydroxyurea in Patients With Advanced Proliferative Chronic Myelomonocytic Leukemia
NCT07033598 is registered in ClinicalTrials.gov with Theradex as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized Phase 2 Study of Pacritinib vs. Hydroxyurea in Patients With Advanced Proliferative Chronic Myelomonocytic Leukemia
- Lead sponsor
- Theradex
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- January 1, 2026
- Completion date
- December 31, 2028
- Enrollment
- 66 (estimated)
- Sites
- 6
Conditions
As the registry lists them; a condition with its own page is linked.